Purple Biotech (STU:1YI0) EPS (Basic): €-331.67 (TTM As of Mar. 2026)


STU:1YI0 Purple Biotech Ltd STU:1YI0
10 GF Score
Price €63.20
! 2 Warning Signs
View Full Analysis

What is Purple Biotech EPS (Basic)?

Purple Biotech STU:1YI0 10 EPS (Basic) is €-331.67 as of Mar. 2026. GuruFocus rates STU:1YI0 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Purple Biotech's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was €-155.70. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €-331.67.

Purple Biotech's EPS (Diluted) for the three months ended in Mar. 2026 was €-155.70. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-331.67.

Purple Biotech's EPS without NRI for the three months ended in Mar. 2026 was €-157.72. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -315.70.

During the past 3 years, the average EPS without NRI Growth Rate was 85.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 43.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was 37.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Purple Biotech's highest 3-Year average EPS without NRI Growth Rate was 85.40% per year. The lowest was -93.50% per year. And the median was 46.90% per year.

Purple Biotech  (STU:1YI0) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Purple Biotech EPS (Basic) Related Terms

Purple Biotech EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Purple Biotech's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Purple Biotech EPS (Basic) Chart

Purple Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -249.57 -4,525.54 -163.23 -42.02 -46.12

Purple Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3,200.50 -3.47 -1.70 -170.80 -155.70
STU:1YI0
10GF Score
Purple Biotech Ltd STU:1YI0
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Purple Biotech EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Purple Biotech's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-22.534-0)/0.480
=-46.95

Purple Biotech's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-0.074-0)/0.932
=-0.08

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-331.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €-331.67 mean?
Purple Biotech (STU:1YI0) has a EPS (Basic) of €-331.67 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Purple Biotech and its competitors.
Is Purple Biotech's EPS (Basic) too high?
Purple Biotech's current EPS (Basic) is €-331.67. Overall, Purple Biotech has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Purple Biotech's EPS (Basic) compare to VRTX and REGN?
Purple Biotech's EPS (Basic) of €-331.67 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Purple Biotech and its competitors. Purple Biotech's current EPS (Basic) is €-331.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Purple Biotech stock overvalued right now?
Purple Biotech (STU:1YI0) has a current EPS (Basic) of €-331.67. The current EPS (Basic) is €-331.67. Purple Biotech's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Purple Biotech (STU:1YI0), the current EPS (Basic) is €-331.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Purple Biotech Business Description

Other Exchanges PPBT:USAPPBT:Israel
Address 4 Oppenheimer Street, Science Park, Rehovot, ISR, 7670104
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.
10GF Score

Get the complete analysis for STU:1YI0

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€63.20
Price